Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2002

View Archived Issues

Novel antibacterial spiro compounds claimed in RiboTargets patent

Synthesis and use of new tachykinin antagonists reported by Boehringer Ingelheim

Senju patents novel Na+/Ca2+ exchange inhibitors

New erythromycin analogues identified at GSK and Pliva

Tanabe Seiyaku presents novel substance P antagonists

Tulane and Biomeasure team claims urotensin-II antagonists

Estrogen receptor modulators and their use in osteoporosis, etc.

Natural products with potent and selective metallo-beta-lactamase-inhibitory activity

Potential antiulcer drug from natural sources under study in Chile

Insmed's oral insulin sensitizer improves glycemic control, lipid profiles and beta-cell function

Dose-response profile for SomatoKine in insulin-requiring type 2 diabetes patients

Evidence of low toxicity reported for the radiotracer [18F]-F-A-85380

The human nicotine conjugate vaccine TA-NIC is reported to be safe for adult smokers

New data on the efficacy and safety of licofelone in the treatment of osteoarthritis

AC-2993 is an effective and safe agent for type 1 and 2 diabetes mellitus

Insulin receptor activator designed by Telik reverses indinavir-induced insulin resistance

Preliminary clinical data reported for components of gene-directed enzyme prodrug therapy

AxCell enters into CRADA with NCI to research TEY1 for prostate cancer

Isis and Lilly expand antisense alliance into cancer

Product R cleared for phase I solid tumor trial

Periostat enters clinical study for meibomianitis

Lorus and NCI collaborate on GTI-2040 phase II program

131I-TM-601 to enter phase I/II for glioma

Phase III results announced for INS-365 Ophthalmic in dry eye

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...